The findings pave the way to consider the relatively poorly investigated Nfe2l1 pathway as a therapeutic target for treating neurodegenerative diseases linked to protein misfolding and promote drug development to enhance its activity. This evidence concerns the gene NFE2L1 and neurodegenerative disease.